Literature DB >> 16364253

AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1.

Woo Je Lee1, Mina Kim, Hye-Sun Park, Hyoun Sik Kim, Min Jae Jeon, Ki Sook Oh, Eun Hee Koh, Jong Chul Won, Min-Seon Kim, Goo Taeg Oh, Michung Yoon, Ki-Up Lee, Joong-Yeol Park.   

Abstract

AMP-activated protein kinase (AMPK) activation increases fatty acid oxidation in skeletal muscle by decreasing malonyl CoA concentrations. However, this may not explain the long-term effects of AMPK activation. Here we show that AMPK activation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) increases mRNA expression of PPARalpha target genes and PGC-1 in cultured muscle cells and mouse skeletal muscle, and that inhibition of PPARalpha and PGC-1 by siRNAs prevents AICAR-stimulated increase in fatty acid oxidation. These data suggest that a novel transcriptional regulatory mechanism involving PPARalpha and PGC-1 exists that is responsible for long-term stimulation of fatty acid oxidation in skeletal muscle by AICAR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364253     DOI: 10.1016/j.bbrc.2005.12.011

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  135 in total

1.  Alpha-lipoic acid supplementation reduces mTORC1 signaling in skeletal muscle from high fat fed, obese Zucker rats.

Authors:  Zhuyun Li; Cory M Dungan; Bradley Carrier; Todd C Rideout; David L Williamson
Journal:  Lipids       Date:  2014-11-01       Impact factor: 1.880

Review 2.  The muscle fiber type-fiber size paradox: hypertrophy or oxidative metabolism?

Authors:  T van Wessel; A de Haan; W J van der Laarse; R T Jaspers
Journal:  Eur J Appl Physiol       Date:  2010-07-03       Impact factor: 3.078

3.  AMPK enhances the expression of pancreatic duodenal homeobox-1 via PPARalpha, but not PPARgamma, in rat insulinoma cell line INS-1.

Authors:  Hua Guo; Shui Sun; Xu Zhang; Xiu-juan Zhang; Ling Gao; Jia-jun Zhao
Journal:  Acta Pharmacol Sin       Date:  2010-07-19       Impact factor: 6.150

Review 4.  AMP-activated protein kinase and its downstream transcriptional pathways.

Authors:  Carles Cantó; Johan Auwerx
Journal:  Cell Mol Life Sci       Date:  2010-07-17       Impact factor: 9.261

5.  Adiponectin is sufficient, but not required, for exercise-induced increases in the expression of skeletal muscle mitochondrial enzymes.

Authors:  Ian R W Ritchie; Tara L MacDonald; David C Wright; David J Dyck
Journal:  J Physiol       Date:  2014-03-31       Impact factor: 5.182

6.  Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3.

Authors:  Ho-Jin Koh; David E Arnolds; Nobuharu Fujii; Thien T Tran; Marc J Rogers; Niels Jessen; Yangfeng Li; Chong Wee Liew; Richard C Ho; Michael F Hirshman; Rohit N Kulkarni; C Ronald Kahn; Laurie J Goodyear
Journal:  Mol Cell Biol       Date:  2006-09-11       Impact factor: 4.272

7.  AMPK regulates basal skeletal muscle capillarization and VEGF expression, but is not necessary for the angiogenic response to exercise.

Authors:  Kevin A Zwetsloot; Lenna M Westerkamp; Burton F Holmes; Timothy P Gavin
Journal:  J Physiol       Date:  2008-10-27       Impact factor: 5.182

Review 8.  Signaling mechanisms in skeletal muscle: acute responses and chronic adaptations to exercise.

Authors:  Katja S C Röckl; Carol A Witczak; Laurie J Goodyear
Journal:  IUBMB Life       Date:  2008-03       Impact factor: 3.885

9.  Normal hypertrophy accompanied by phosphoryation and activation of AMP-activated protein kinase alpha1 following overload in LKB1 knockout mice.

Authors:  Sean L McGee; Kirsty J Mustard; D Grahame Hardie; Keith Baar
Journal:  J Physiol       Date:  2008-01-17       Impact factor: 5.182

10.  The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.

Authors:  C M Werner; S H Schirmer; C Gensch; V Pavlickova; J Pöss; M B Wright; M Böhm; U Laufs
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.